BioPlx Says It Can Stop Recurrent MRSA Cycles In Hospitals
Would Use Strain Substitution To Prevent Superbugs
Executive Summary
Emerging Company Profile: Privately held BioPlx is a US-based platform biotech that has successfully raised more than $10m from investors with the promise of developing non-antibiotic ways to control multiple-drug resistant superbugs and other infectious diseases.
You may also be interested in...
UK, Sweden Test Differing Antibiotic Market Models
Sweden and the UK are conducting differing ‘develop and test’ programs to assess so-called ‘pull’ incentives in which an antibiotics innovator will be paid an annual fee in return for an access guarantee for anti-infectives. The projects have drawn keen attention from other countries.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.